AR123933A1 - ISOXAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT₂A RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - Google Patents

ISOXAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT₂A RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Info

Publication number
AR123933A1
AR123933A1 ARP210102981A ARP210102981A AR123933A1 AR 123933 A1 AR123933 A1 AR 123933A1 AR P210102981 A ARP210102981 A AR P210102981A AR P210102981 A ARP210102981 A AR P210102981A AR 123933 A1 AR123933 A1 AR 123933A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
cycloalkyl
phenyl
independently selected
Prior art date
Application number
ARP210102981A
Other languages
Spanish (es)
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of AR123933A1 publication Critical patent/AR123933A1/en

Links

Landscapes

  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporciona un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de este, que es un modulador de 5-HT₂A y puede usarse en el tratamiento de enfermedades y trastornos asociados con la expresión y/o actividad del receptor de serotonina 5-HT₂A. Por lo tanto, también se proporcionan métodos de tratamiento de enfermedades y trastornos relacionados con 5HT₂A. Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de este, en donde: R¹ se selecciona de alquilo C₁₋₆, cicloalquilo C₃₋₆, fenilo, heteroarilo de 5 - 10 miembros, heterocicloalquilo de 5 - 9 miembros, (alquilen C₁₋₃)-(cicloalquilo C₃₋₆), (alquilen C₁₋₃)-fenilo, (haloalquilen C₁₋₃)-fenilo, (alquilen C₁₋₃)-(heteroarilo de 5 - 10 miembros), (alquilen C₁₋₃)-(heterocicloalquilo de 5 - 9 miembros), (alquilen C₁₋₃)-O-(cicloalquilo C₃₋₆) y (alquilen C₁₋₃)-NH-(cicloalquilo C₃₋₆), en donde el alquilo, alquileno, cicloalquilo, fenilo, heteroarilo y heterocicloalquilo están, cada uno, opcionalmente sustituidos con uno o más sustituyentes seleccionados independientemente de halógeno, -CN, -OH, -NH₂, alquilo C₁₋₃, (haloalquilo C₁₋₃), (cicloalquilo C₃₋₆), -O-(alquilo C₁₋₃), (alquilen C₁₋₃)-O-(alquilo C₁₋₃) y fenilo; R² se selecciona de heterocicloalquilo de 4 - 6 miembros, (alquilen C₁₋₃)-(heterocicloalquilo de 4 - 10 miembros) y (alquilen C₁₋₃)-NR²AR²B, en donde el alquileno y heterocicloalquilo están, cada uno, opcionalmente sustituidos con uno o más sustituyentes seleccionados independientemente de halógeno, oxo, -OH, (alquilo C₁₋₃), -O-(alquilo C₁₋₃), (alquilen C₁₋₃)-C(O)OH, -C(O)H, -C(O)OH, -C(O)(alquilo C₁₋₃), -C(O)(alquilen C₁₋₃)-OH, -C(O)C(O)OH y -SO₂(alquilo C₁₋₃); R²A y R²B se seleccionan cada uno independientemente de H, alquilo C₁₋₃, haloalquilo C₁₋₃, cicloalquilo C₃₋₆, (alquilen C₁₋₃)-O-(alquilo C₁₋₃), (alquilen C₁₋₃)-OH, (alquilen C₁₋₃)-(cicloalquilo C₃₋₆), (alquilen C₁₋₃)-S(=O)-(alquilo C₁₋₃), (alquilen C₁₋₃)-SO₂-(alquilo C₁₋₃) y C(=NH)(alquilo C₁₋₃); o R²A y R²B, tomados junto con el nitrógeno al cual están unidos, forman un anillo heterocicloalquilo de 3 - 10 miembros opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, oxo, -OH, alquilo C₁₋₃, (haloalquilo C₁₋₃), -O-(alquilo C₁₋₃), (alquilen C₁₋₃)-C(O)OH, -C(O)H, - C(O)(alquilo C₁₋₃), -C(O)(alquilen C₁₋₃)-OH, -C(O)C(O)OH y -SO₂(alquilo C₁₋₃), y que opcionalmente contiene un heteroátomo adicional seleccionado del grupo de N, O y S; R³ y R⁴ se seleccionan cada uno independientemente de H, alquilo C₁₋₆ y haloalquilo C₁₋₆; y R⁵ se selecciona de H y alquilo C₁₋₆.There is provided a compound of formula (1) or a pharmaceutically acceptable salt thereof, which is a modulator of 5-HT₂A and can be used in the treatment of diseases and disorders associated with the expression and/or activity of the serotonin 5-HT₂A receptor. . Therefore, methods of treating diseases and disorders related to 5HT₂A are also provided. Claim 1: A compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein: R¹ is selected from C₁₋₆ alkyl, C₃₋₆ cycloalkyl, phenyl, 5-10 membered heteroaryl, 5-9 membered heterocycloalkyl , (C₁₋₃ alkylene)-(C₃₋₆ cycloalkyl), (C₁₋₃ alkylene)-phenyl, (C₁₋₃ haloalkylene)-phenyl, (C₁₋₃ alkylene)-(5-10 membered heteroaryl), ( C₁₋₃ alkylene)-(5-9 membered heterocycloalkyl), (C₁₋₃ alkylene)-O-(C₃₋₆ cycloalkyl) and (C₁₋₃ alkylene)-NH-(C₃₋₆ cycloalkyl), wherein the alkyl, alkylene, cycloalkyl, phenyl, heteroaryl, and heterocycloalkyl are each optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, -NH₂, C₁₋₃ alkyl, (C₁₋₃ haloalkyl), ( C₃₋₆ cycloalkyl), -O-(C₁₋₃ alkyl), (C₁₋₃ alkylene)-O-(C₁₋₃ alkyl) and phenyl; R² is selected from 4-6 membered heterocycloalkyl, (C₁₋₃ alkylene)-(4-10 membered heterocycloalkyl) and (C₁₋₃ alkylene)-NR²AR²B, wherein alkylene and heterocycloalkyl are each optionally substituted with one or more substituents independently selected from halogen, oxo, -OH, (C₁₋₃ alkyl), -O-(C₁₋₃ alkyl), (C₁₋₃ alkylene)-C(O)OH, -C(O)H , -C(O)OH, -C(O)(C₁₋₃ alkyl), -C(O)(C₁₋₃ alkylene)-OH, -C(O)C(O)OH and -SO₂(C₁ alkyl ₋₃); R²A and R²B are each independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, (C₁₋₃ alkylene)-O-(C₁₋₃ alkyl), (C₁₋₃ alkylene)-OH , (C₁₋₃ alkylene)-(C₃₋₆ cycloalkyl), (C₁₋₃ alkylene)-S(=O)-(C₁₋₃ alkyl), (C₁₋₃ alkylene)-SO₂-(C₁₋₃ alkyl) and C(=NH)(C₁₋₃ alkyl); or R²A and R²B, taken together with the nitrogen to which they are attached, form a 3-10 membered heterocycloalkyl ring optionally substituted with one or more substituents independently selected from halogen, oxo, -OH, C₁₋₃ alkyl, (C₁₋ haloalkyl ₃), -O-(C₁₋₃ alkyl), (C₁₋₃ alkylene)-C(O)OH, -C(O)H, -C(O)(C₁₋₃ alkyl), -C(O) (C₁₋₃ alkylene)-OH, -C(O)C(O)OH and -SO₂(C₁₋₃ alkyl), and optionally containing one additional heteroatom selected from the group of N, O and S; R³ and R⁴ are each independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and R⁵ is selected from H and C₁₋₆ alkyl.

ARP210102981A 2020-10-27 2021-10-27 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT₂A RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO AR123933A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063106156P 2020-10-27 2020-10-27

Publications (1)

Publication Number Publication Date
AR123933A1 true AR123933A1 (en) 2023-01-25

Family

ID=85131271

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102981A AR123933A1 (en) 2020-10-27 2021-10-27 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT₂A RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Country Status (1)

Country Link
AR (1) AR123933A1 (en)

Similar Documents

Publication Publication Date Title
AR104176A1 (en) IDO INHIBITORS (INDOLAMINE-2,3-DIOXYGENASE)
AR086828A1 (en) FUSIONED HETEROCICLICAL COMPOUNDS AS IONIC CHANNEL MODULATORS
AR104025A1 (en) PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND / OR ABHD6, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
AR108709A1 (en) FXR MODULATING COMPOUNDS (NR1H4)
AR114793A1 (en) MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES OF THEM
AR104720A1 (en) CCR2 MODULATORS
AR112834A1 (en) RAPAMYCIN DERIVATIVES
AR115092A1 (en) MAGL INHIBITORS
AR113299A1 (en) ISOINDOLINE COMPOUNDS
AR114417A1 (en) COMPOUNDS AND METHODS OF USE
AR103251A1 (en) CARBAMOILPIRIDONE POLICYCLY COMPOUNDS AND THEIR PHARMACEUTICAL USE
AR086792A1 (en) COMPOUNDS FOR ADDICTION TREATMENT
AR116114A1 (en) HETEROCYCLIC AMIDAS BETWEEN 5 AND 7 MEMBERS AS JAK INHIBITORS
AR119010A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF USE
AR111808A1 (en) PIRIMIDINE DERIVATIVES AS PGE2 RECEIVER MODULATORS
AR119244A1 (en) 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
AR111494A1 (en) ANILINOQUINAZOLINE C₅ COMPOUNDS AND ITS USE IN CANCER TREATMENT
AR119234A1 (en) IMIDAZO[1,2-A]PYRIDINIL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
AR117229A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
AR120773A1 (en) DERIVATIVES OF 3-(5-METHOXY-1-OXOISOINDOLIN-2-IL)PIPERIDIN-2,6-DIONE AS REDUCERS OF THE ACTIVITY OF WIZ PROTEIN
AR112794A1 (en) HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE IN THE TREATMENT OF DISEASES INDUCED BY IDH MUTATIONS
AR118641A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS
AR115906A1 (en) HALOALYLAMINE SULFONE DERIVATIVES AS LYSYL OXIDASE INHIBITORS
AR122407A1 (en) COMPOSITIONS AND METHODS FOR TREATING INTESTINAL INFLAMMATION USING A CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES
AR120170A1 (en) 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS

Legal Events

Date Code Title Description
FB Suspension of granting procedure